Leerink Partners analyst Thomas Smith has reiterated their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...

Viridian Therapeutics (VRDN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami ...

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) have received a consensus recommendation of “Moderate ...

Wells Fargo has recently reduced Viridian Therapeutics Inc (VRDN) stock to Equal Weight rating, as announced on December 19, 2024, according to Finviz. Earlier, on November 25, 2024, TD Cowen had ...

Viridian Therapeutics, Inc. (VRDN) today announced that Stephen Mahoney has been appointed the company’s President and Chief Executive Officer, and a member of the Board of... ByInvesting.com ...

The projected fair value for Viridian Therapeutics is US$14.53 based on 2 Stage Free Cash Flow to Equity Viridian Therapeutics' US$19.31 share price signals that it might be 33% overvalued The US$ ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Viridian Therapeutics is based in Waltham, MA. The company is focused on developing treatments for serious and rare diseases. The company's two most advanced candidates in the clinic (VRDN-001 and ...

10 analysts have expressed a variety of opinions on Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

This page features the latest news about the Viridian Therapeutics stock. Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and ...